Here is the final consolidated review.

---

## Summary

ProteinVista proposes a 3D CNN that operates on voxelized full-atom protein structures, pretrained on ~500K AlphaFold2 structures (two orders of magnitude less data than sequence-based protein language models). It is evaluated on protein-ligand binding tasks (transporter-substrate classification, enzyme-substrate classification, IC50 regression) and one homology-based task (GO annotation). The key finding is that the 3D CNN matches or exceeds ESM-2 on structure-sensitive tasks while using substantially less compute, and that sequence and structure embeddings are partially complementary.

## Strengths

- **Well-documented compute advantage with concrete numbers (Section 4.3, Figure 3).** Pretraining took 48 hours on 4 A100 GPUs (~500K structures) vs. ~7 days on 128 H100 GPUs for ESM-2_650M (~250M sequences) — roughly a 100× reduction in GPU-hours. Training throughput for inference is 20s per 1000 proteins vs. 426s for ESM-2_650M. These are grounded, specific comparisons.

- **Systematic ablation studies (Section 4.2, Figure 2e).** The paper tests the impact of: number of augmented inference views (5→1 drops R² by 6.4%), presence of augmentations during fine-tuning (-0.1%, effectively zero), choice of pretraining objective (contrastive vs. Rosetta regression, +1.0%), and voxel resolution (1.0Å→1.5Å drops R² by 1.1%). This allows the reader to assess which design choices actually matter.

- **Performance stratification by sequence identity, TM-score, and pLDDT (Section 4.1, Figure 2a-d).** Showing *when* structural information helps (high-confidence, well-represented structures) and when it does not (low-homology regimes) is informative. The complementarity story — sequence and structure models help in different regimes — is the paper's most convincing narrative.

- **IC50 regression result (R²=0.69 vs. 0.60–0.61 for ESM-2, Table 2) is a genuine and large improvement** on a practically relevant task (drug-target affinity prediction). The p-value is astronomical (p < 10⁻³⁰⁴), and the ~13% relative improvement in R² is meaningful.

- **Honest reporting of a negative result (Section 3.4).** The paper shows that ProteinVista underperforms ESM-2 on GO annotation (F_max 0.57 vs 0.62), which is consistent with its own thesis (structure helps on structure-dependent tasks, not homology-based ones). This transparency strengthens credibility.

## Weaknesses

### Fatal
None.

### Major

1. **Contrastive pretraining distills from ESM-2, making the "outperforms" framing asymmetric.**  
   The primary pretraining objective (Section 2.3, Figure 1d) is a contrastive alignment that pulls ProteinVista's structure embedding toward the ESM-2 embedding of the same protein and pushes it away from others. The method is trained to make its representations resemble ESM-2's representations. Then the paper compares this model against ESM-2 and uses "outperforms sequence transformers" in the title and abstract. This is a student-teacher comparison where the student had access to the teacher's representations during training.  

   **The paper partially mitigates this** through the ablation in Section 4.2, which shows that the Rosetta-only pretrained model (no ESM-2 distillation) achieves only 1.0% lower R² on IC50 — demonstrating that most of ProteinVista's capability does *not* depend on ESM-2 distillation. However, the main results, tables, title, and abstract all feature the contrastively-pretrained model as the primary showcase. The framing should be restructured: the Rosetta-only version should be foregrounded as the fair baseline against ESM-2, or the distillation should be clearly labeled as such in the title and abstract.

### Minor

2. **The SOTA comparison uses an ensemble, not ProteinVista alone.**  
   In Table 1, the rows that surpass existing SOTA methods (SPOT, ProSmith-ESP, Fusion_ESP) are "ESM-ProteinVista_OP" — an optimized pipeline combining predictions from *both* ProteinVista *and* ESM-2_650M. ProteinVista alone achieves 90.8% on TSP vs. SPOT's 92.4%, and 91.8% on ESP vs. ProSmith-ESP's 94.2%. The paper states "ESM-ProteinVista_OP surpasses the current best models" (Section 3.3), which is technically true for the ensemble, but the reader could misinterpret this as ProteinVista alone beating SOTA. The standalone ProteinVista result against SOTA methods should be made more prominent.

3. **The speed comparison has an unexplained inconsistency between FLOPs and wall time.**  
   Section 4.3 reports 415 GFLOPs for ProteinVista vs. 520 GFLOPs for ESM-2_650M (a ~1.25× ratio), yet training throughput is 20s per 1000 proteins for ProteinVista vs. 426s for ESM-2_650M (a ~21× ratio). The paper's explanation — "computations for the 3D CNN can be parallelized more efficiently" — is vague and does not adequately bridge this order-of-magnitude gap. Possible factors (memory-bandwidth bottlenecks in attention, different batch-size scaling properties, preprocessing time differences) are not analyzed. As presented, the reader cannot tell whether these throughput numbers measure comparable things.

4. **The ESM-2 variant used as the teacher for contrastive pretraining is not specified.**  
   Section 2.3 says "We projected ESM-2 sequence embeddings" but does not state whether ESM-2_150M, ESM-2_650M, or another variant was used. This matters for contextualizing the comparison: if the larger model (650M) was used as teacher, comparing ProteinVista against ESM-2_150M is particularly asymmetric.

5. **No discussion of potential protein-level leakage in BindingDB.**  
   The IC50 regression (Table 2) uses BindingDB, a well-known dataset where the same protein can appear with different ligands. The paper does not confirm whether any protein appears in both training and test partitions, which is a standard concern in drug-target interaction benchmarks.

### Trivial

6. **Minor internal inconsistency in ablation values.**  
   The text (line 170) reports the contrastive vs. Rosetta difference as "1.0%", while the table embedded in the figure caption (line 184) lists "~1.2%". These should be consistent.

## Nice-to-Haves

- A breakdown of the 21× wall-time vs. 1.25× FLOPs discrepancy (memory bandwidth, batch-size scaling, data preprocessing) would strengthen the compute-efficiency claim.
- Clarifying whether test-time augmentation is needed at inference for all benchmarks, and what happens at arbitrary (non-90°) rotation angles, would improve the rotation-robustness discussion.
- An investigation into storage cost: 75 GB for 5800 proteins (~13 MB/protein) scales to ~6.5 TB for the full pretraining set, a practical deployment consideration worth discussing.

## Removed Points

- **"Rotation invariance through data augmentation is demonstrably incomplete"** (original Issue 4): Removed as overstated. The paper uses "rotation-robust" (not "invariant") and 90° discrete augmentations paired with test-time averaging are a standard approach. The 6.4% drop when reducing from 5→1 view is honestly reported and characterizes the approach's limitation rather than being a flaw.
- **Section-by-section notes about "novelty claim is narrow" and "architectural novelty is limited":** Removed as opinion without concrete evidence of deception. The paper clearly states its contribution as a *scaled-up* full-atom 3D CNN with pretraining, which is specific enough.
- **Notes about p-values implying practical importance**: Removed. The reviewer correctly notes that significance with large N is expected, but this is a standard practice and the IC50 R² improvement is large enough to be practically meaningful regardless.
- **"Abstract overstates the case" on outperforming sequence transformers broadly**: Partially incorporated into Major Issue 1 above; the specific note about GO annotation underperformance was reframed as a strength (honesty) in the strengths section.
- **Missing appendix reference complaints**: Removed per policy (parser strips appendices from all papers).

## Novel Insights

The reviews surface a specific tension that the paper does not fully resolve: the "outperforms" claim is strongest on IC50 regression (where the Rosetta-only ablation confirms independence from ESM-2 distillation) but weakest on the classification benchmarks where the SOTA comparison relies on an ESM-2 ensemble. This means the paper actually contains two different claims — (a) ProteinVista's structure encoding genuinely helps on affinity prediction, and (b) the combination of structure and sequence helps on classification — and the evidence is stronger for (a) than (b). The framing should better reflect this asymmetry.

## Suggestions

1. Restructure the main results to present the **Rosetta-pretrained-only model as the primary baseline** against ESM-2, with the contrastive variant clearly labeled as incorporating knowledge distillation from the very model it is compared against.
2. Add a row to Table 1 showing ProteinVista alone (with the optimized pipeline but without mixing ESM-2 predictions) against the SOTA methods, so readers can assess the standalone contribution.
3. Provide a more detailed analysis of the speed discrepancy, breaking down wall time into forward pass, backward pass, data loading, and preprocessing components for both architectures.
4. Specify which ESM-2 variant provides the teacher embeddings in Section 2.3.
5. Add a sentence about protein-level train/test separation for the BindingDB benchmark.

## Score and Decision

**Bracket determination.** Round 1 bracketing retrieved anchors across score ranges. The most comparable papers are: **ProteiNexus** (3.67, protein structure pretraining with fatal data leakage and absent baselines — ProteinVista is clearly stronger); **ProteinAdapter** (3.40, marginal ESM-1b improvements with insufficient baselines — ProteinVista has cleaner comparisons); **CheapNet** (6.00, protein-ligand affinity prediction with comprehensive evaluation but minor novelty concerns); **GroupBind** (6.75, strong docking idea with some comparison fairness concerns). ProteinVista aligns closest with the 5.5–7.0 band: its evidence base is stronger than 4–5 range papers (better ablations, honest negative results, no data leakage), but its central framing asymmetry prevents it from reaching the 7+ band (where papers like GroupBind sit with cleaner comparative claims despite other limitations). The initial bracket was 5.5–7.0.

**Anchor comparison.** CheapNet (6.00) is the tightest match: both are protein-ligand binding papers with moderate architectural novelty and thorough empirical evaluation. ProteinVista has stronger ablations and compute analysis than CheapNet but a more significant framing concern (ESM distillation). On balance, these offset to a similar level. GroupBind (6.75) has a cleaner comparison framework, placing it slightly above. No paper in the retrieved set shares ProteinVista's specific ESM-distillation framing issue, so the 6.0 anchor is conservative.

**Final score based on weighted-item comparison.** Shared positive heavy-weight items with CheapNet: comprehensive experiments (+3), clear motivation (+2), code availability (+1). Missing positive items relative to GroupBind: cleaner comparison claims (+4 for GroupBind's strength that ProteinVista lacks due to the distillation asymmetry). Shared negative items: some comparison fairness concerns (-3 to -4 in both). The distillation framing is the single heaviest negative item specific to this paper. Given that the contribution is real and the ablation resolves the technical concern (leaving only a framing issue), 6.0 reflects a clear accept with necessary revisions.

**MY FINAL SCORE: <score>6.0</score>**
**MY FINAL DECISION: <decision>Accept</decision>**